XOMA Royalty Corporation

DB:X0M1 Stock Report

Market Cap: €340.2m

XOMA Royalty Valuation

Is X0M1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of X0M1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate X0M1's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate X0M1's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for X0M1?

Key metric: As X0M1 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for X0M1. This is calculated by dividing X0M1's market cap by their current revenue.
What is X0M1's PS Ratio?
PS Ratio16.5x
SalesUS$21.61m
Market CapUS$354.31m

Price to Sales Ratio vs Peers

How does X0M1's PS Ratio compare to its peers?

The above table shows the PS ratio for X0M1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.6x
HPHA Heidelberg Pharma
12.3x16.6%€103.9m
FYB Formycon
13.6x33.4%€827.2m
BIO3 Biotest
1.5x3.6%€1.4b
MDG1 Medigene
3x16.1%€22.6m
X0M1 XOMA Royalty
16.5x31.3%€354.3m

Price-To-Sales vs Peers: X0M1 is expensive based on its Price-To-Sales Ratio (16.5x) compared to the peer average (7.6x).

Price to Sales Ratio vs Industry

How does X0M1's PS Ratio compare vs other companies in the DE Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
V9Z Aceragen
0.3x-161.8%US$2.18m
X0M1 16.5xIndustry Avg. 7.9xNo. of Companies6PS0612182430+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: X0M1 is expensive based on its Price-To-Sales Ratio (16.5x) compared to the European Biotechs industry average (8x).

Price to Sales Ratio vs Fair Ratio

What is X0M1's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

X0M1 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio16.5x
Fair PS Ratio6.5x

Price-To-Sales vs Fair Ratio: X0M1 is expensive based on its Price-To-Sales Ratio (16.5x) compared to the estimated Fair Price-To-Sales Ratio (6.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst X0M1 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€28.40
€80.24
+182.5%
36.0%€109.16€51.32n/a2
Nov ’25€27.20
€74.69
+174.6%
41.0%€105.29€44.10n/a2
Oct ’25€23.60
€74.69
+216.5%
41.0%€105.29€44.10n/a2
Sep ’25€26.20
€75.35
+187.6%
41.0%€106.21€44.48n/a2
Aug ’25€24.40
€53.46
+119.1%
27.6%€68.21€38.72n/a2
Jul ’25€21.60
€53.46
+147.5%
27.6%€68.21€38.72n/a2
Jun ’25€22.80
€53.46
+134.5%
27.6%€68.21€38.72n/a2
May ’25€24.40
€53.31
+118.5%
29.8%€69.21€37.41n/a2
Feb ’24€18.40
€60.66
+229.7%
10.4%€66.96€54.35n/a2
Jan ’24€17.00
€60.66
+256.8%
10.4%€66.96€54.35n/a2
Dec ’23€23.00
€60.66
+163.7%
10.4%€66.96€54.35€13.402
Nov ’23€16.80
€61.34
+265.1%
10.4%€67.72€54.96€17.602

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Perrigo

US$3.7b

Provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally.

PIG

US$25.74

7D

1.9%

1Y

-7.4%

Aspen Pharmacare Holdings

R75.5b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.95

7D

0.6%

1Y

4.7%

Merck

US$252.6b

Operates as a healthcare company worldwide.

6MK

US$97.10

7D

6.7%

1Y

3.9%